HCA Thought Most Dropping-Off Patients Would Find Other Insurance. Almost None Did.

A law firm named Kirby McInerney sent out a press release on July 20 asking HCA Healthcare shareholders to get in touch. The company, the release said, might have violated federal securities laws. No lawsuit has been filed. Kirby McInerney is fishing.

But the fish here is worth looking at. It's not the press release. It's the gap between what HCA told investors about how many of its patients would go uninsured, and what actually happened.

HCA is the largest for-profit hospital system in the United States, with 190 hospitals and roughly 2,500 ambulatory sites. In January 2026, enhanced federal tax credits that subsidized Affordable Care Act health insurance premiums expired. Anyone who followed policy knew that millions of people would lose their exchange coverage. What was supposed to be a manageable headwind turned into a bigger problem than HCA's own financial model could account for.

Here's the specific number that matters. HCA told investors it expected 80% to 85% of patients who dropped off the ACA exchanges to go fully uninsured, with the remaining 15% to 20% finding other coverage - an employer plan, Medicaid, something else. That assumption drove HCA's early-2026 guidance, where the company projected the ACA fallout would cost it between $600 million and $900 million for the full year.

Then came the second quarter, and the assumption cracked. HCA reported a $400 million hit to income before taxes in Q2 alone from the payer mix shift. That's more than half of the company's original full-year estimate, realized in a single quarter. On July 14, HCA slashed its full-year impact forecast from $600 million to $900 million, up to $1 billion to $1.2 billion.

But the weirder detail came on the July 24 earnings call, not in the July 14 press release. CEO Sam Hazen told analysts that the company's coverage estimates around how many patients would leave the exchanges were "generally accurate." The problem wasn't how many people dropped off. The problem was what happened next.

"We expected some of these patients to shift to other forms of coverage, but this did not happen," Hazen said. "Instead, these patients migrated almost one for one to uninsured."

Almost 100%, versus the 80% to 85% the company had been telling investors. That 15-percentage-point gap between expectation and reality is roughly what turned a $600 million to $900 million problem into a $1 billion to $1.2 billion one. And HCA, which sits at the pointy end of the healthcare system and sees patient insurance status the moment they walk through the door, is the company that should have known first.

The securities fraud investigation is still in its earliest phase. Kirby McInerney, along with several other plaintiff firms including Kessler Topaz Meltzer & Check and Schall, Brown & Schwartz, are all asking shareholders to contact them. No complaint has been filed.

The standard template for a securities class action works like this: the company makes forward-looking statements, those statements turn out to be wrong, the stock drops, and lawyers argue the company knew the statements were wrong when it made them. The key word is knew - or should have known.

So the real question for investors is not whether HCA's model was off. Models get revised. The question is whether HCA's internal data showed the migration-to-uninsured rate was higher than 80-85% before July 14, and the company waited to disclose it.

The timeline is tight. HCA lost $150 million to the ACA impact in the first quarter, then $400 million in the second. The company itself acknowledged in its July 14 release that it had already increased its Q1 estimate by $75 million during Q2, suggesting it was revising its understanding of the problem as the quarter progressed. CFO Michael Marks said on the earnings call that exchange-related dropoffs comprise about 80% of uninsured volume growth, with the remainder tied to Medicaid conversion slowdowns, mostly in Texas.

HCA's stock fell nearly 7% on July 14, closing at $363.60. As of this writing, it has partially recovered to around $407 but is still down roughly 13% year-to-date and about 19% over the past four months. The stock trades well below its 52-week high of $556.52.

This isn't the first time HCA has been on the receiving end of securities litigation. In 2015, the company settled a class action for $215 million related to its 2005 IPO. The claim was that HCA knew its high-margin cardiac procedure volumes were declining before the offering and failed to disclose it - the stock then fell 40% from the IPO price. Before that, in 2000, the predecessor entity paid $840 million in what was then the largest government fraud settlement in U.S. history, after the DOJ found systematic billing abuses across its hospitals.

I mention this not because HCA is a repeat offender - the 2000 case was about billing practices, and the 2015 case was about IPO disclosure, neither of which is the same as this year's guidance revision. I mention it because plaintiff lawyers notice patterns. A company that has settled for large amounts before is a known venue for recovery, and that changes the calculus of whether firms invest time in building a case.

The economic mechanism here is straightforward once you strip the legal framing away. Hospitals make money from the gap between what a payer reimburses and what care costs to deliver. An insured patient generates a margin. An uninsured patient generates a loss, or at best a small recovery through charity-care provisions that don't cover full cost. When a whole cohort of patients shifts from "insured" to "uninsured" faster than the hospital modeled, the profit forecast has to come down.

HCA's revenue guidance barely moved - $77 billion to $79.5 billion, only slightly narrower than the prior $76.5 billion to $80 billion. Revenue is volume times price, and volume didn't collapse; inpatient admissions were up 2.5%, ER visits up 3.6%. The problem is that more of that volume now comes from patients whose bills don't get paid. Same revenue, worse margin.

The secondary headwind is surgical volume. Same-facility inpatient surgeries declined 2.3% and outpatient surgeries fell 3.4%. Uninsured patients don't schedule elective procedures. That's not a disclosure problem - it's the mechanical consequence of people who can't afford insurance also not affording knee replacements.

On the other side, HCA got about $400 million in incremental benefit from Medicaid supplemental payment programs, largely from a Florida state-directed payment program approved by CMS during the quarter. So the machine is both bleeding and being patched at the same time.

The simplest model is this: HCA knew ACA subsidies were expiring. It built a model to forecast the financial impact. The model assumed some fraction of dropping patients would find alternative coverage. That assumption turned out to be too generous - almost nobody did. The question for the lawyers, and for investors watching the stock, is whether the company's own patient-level data should have corrected that assumption months earlier.

Whether a securities complaint gets filed, let alone survives a motion to dismiss, depends on whether plaintiffs can show HCA's earlier guidance was materially misleading at the time it was made, not merely revised in light of new information. That's a factual question that isn't resolvable from press releases.

What is resolvable is that HCA's earnings outlook now reflects a structural hit - $1 billion to $1.2 billion to income before taxes - from a policy change that was known well in advance. The company kept its $5 billion to $5.5 billion capital spending plan intact and approved more than $7 billion in new expenditures coming online over the next three years. Management is betting that demand growth of 2% to 3% from population growth and capacity additions will outpace the payer mix problem.

The insurance system is leaky. Patients fall through gaps. The hospital that sees them first is the one that has to absorb the cost. HCA built a model, the model was wrong in a direction it should have been able to test, and now the lawyers are checking whether the gap between the model and reality is a mistake or a disclosure problem. That distinction - between bad forecasting and misleading guidance - is usually where these cases live or die.